Saturday, October 31, 2026

LendingTree Stock Over 27% Up In The Last 10 Sessions

LendingTree Stock Over 27% Up In The Last 10 Sessions

LendingTree (NASDAQ: TREE), a leading online lending marketplace, has recently experienced a significant increase in its share value. Over the course of 10 trading sessions, LendingTree's shares soared by over 27.14%, rising from .33 to .12 as of Monday's close, as reported by VIANEWS. This considerable increase is particularly notable, given the broader context of the NASDAQ Index, which, although having posted gains, has seen consecutive drops and only managed to gain 0.211% overall since Jan 1st, 2019.

LendingTree's Current Status and Performance

As of Monday, LendingTree shares closed 46.37% below its 52-week high. This may indicate that the company's stocks are currently undervalued, considering the performance of its operations and profitability measures. Interestingly, LendingTree managed to boast an EPS of 13.54 last year, even though the company went through a period of negative return on equity of -57.24%, over the past year.

Trading Volume and Volatility

However, in recent times, the company has reported a trading volume of only 82,158 shares - a number significantly less than its average of 327,660. This decreased trading volume combined with the recent sudden increase in price may suggest a lack of liquidity in the market, potentially making its price more volatile than usual. Speaking of volatility, LendingTree's average intraday variations were 1.23% last week, 1.15% last month, and 4.18% last quarter, with their highest amplitude reported as 2.15% last week, 3.55% last month, and 4.18% last quarter.

EBITDA and Financial Performance

The company's EBITDA currently stands at -563.25, a figure that may suggest difficulties in managing operating costs or generating sufficient revenue. However, the recent surge in the stock price indicates that some shareholders might anticipate better financial outcomes in the near future.

Conclusion

Investors must consider a blend of financial performance indicators and market behaviors when developing their trading decisions. While investors who own LendingTree stock have enjoyed profits in the past week, the company's negative ROE and EBITDA ratios, along with market volatility issues, present long-term risks that necessitate careful monitoring for devising a flourishing trading strategy.

More news about LendingTree (TREE).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com